Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

Omega Therapeutics, Inc. announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven HCC, in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase I/II MYCHELANGELO™ I clinical trial.